Review
Nature Reviews Immunology 4, 24-35 (January 2004) | doi:10.1038/nri1256
Dendritic cells: emerging pharmacological targets of immunosuppressive drugs
Holger Hackstein1 & Angus W. Thomson2 About the authors
Abstract
Immunosuppressive drugs have revolutionized organ transplantation and improved the therapeutic management of autoimmune diseases. The development of immunosuppressive drugs and understanding of their action traditionally has been focused on lymphocytes, but recent evidence indicates that these agents interfere with immune responses at the earliest stage, targeting key functions of dendritic cells (DCs). Here, we review our present understanding of how classical and new immunosuppressive agents interfere with DC development and function. This knowledge might provide a rational basis for the selection of immunosuppressive drugs in different clinical settings and for the generation of tolerogenic DCs in the laboratory.
- View At a Glance
Author affiliations
- Institute for Clinical Immunology and Transfusion Medicine, Justus-Liebig University Giessen, Langhansstr. 7, D-35392 Giessen, Germany.
- Thomas E. Starzl Transplantation Institute and Department of Immunology, University of Pittsburgh, 200 Lothrop Street Biomedical Science Tower W1544, Pittsburgh, Pennsylvania 15213, USA.
Correspondence to: Holger Hackstein1 Email: holger.hackstein@immunologie.med.uni-giessen.de
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Toll-like receptor?mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathwayNature Immunology Article (01 Oct 2008)
See all 2 matches for Research
